The Peter Attia Drive

Podbit · The Peter Attia Drive

#403 ‒ Peptides: separating scientific promise from marketing hype

Explore episode Aug 10, 2026
Health & Fitness
CJC-1295: Biologically Active, Clinically Unproven

#403 ‒ Peptides: separating scientific promise from marketi… · Aug 10, 2026 Health & Fitness

CJC-1295 raises growth hormone and IGF-1 — that much is real. But we already know what happens when you directly administer growth hormone to replete adults: underwhelming results. An indirect releaser is unlikely to produce dramatically different outcomes, and the clinical evidence to prove otherwise simply doesn't exist.

Where this was said

CJC-1295: biological activity versus meaningful clinical benefit

At 23:50 · chapter starts 23:30

Shifting to the bucket above BPC-157, Peter uses CJC-1295 to illustrate how biological activity can be real and yet clinically meaningless. CJC-1295 does raise growth hormone and IGF-1 — that is not in dispute. But Peter frames the critical question: do those biological changes translate into outcomes that actually matter? Strength, recovery, performance, quality of life? The most direct way to interrogate the growth hormone pathway is to administer growth hormone itself. In growth hormone-deficient patients, replacement matters significantly. In specific conditions like HIV-associated lipodystrophy, targeting this pathway has dramatic benefits. But in growth hormone-replete adults — essentially everyone listening — the results are surprisingly underwhelming. Growth hormone produces modest changes in body composition, but a meaningful portion of the increase in so-called lean body mass reflects water retention and non-contractile tissue rather than functional muscle. Strength, physical performance, and quality of life benefits are generally absent or tiny. If directly administering growth hormone fails to move the needle, Peter argues, the burden of proof for an indirect growth hormone-releasing agent like CJC-1295 producing dramatically different outcomes is extremely high — and the evidence to meet that burden simply does not exist.

Similar podbits

Health & Fitness
AI in Healthcare: Where It Helps and Where It Doesn't

Using AI to Increase Your Intelligence & Enrich Humanity | … · Aug 10, 2026 Health & Fitness

AI nailed Andrew Huberman's vertigo-vs-low-blood-pressure diagnosis because that pattern has been reported millions of times. But every patient's liver is different and data on liver surgeries is scarce worldwide — making solo robot surgery dangerous. The rule is simple: data abundance means AI can help; data scarcity means keep the human in the loop.